

Febuxostat (Uloric)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Febuxostat (Uloric)	1
Summary	1
Definitions	2
Medical Necessity Criteria for Initial Clinical Review	3
Initial Indication-Specific Criteria	3
Gout	3
Tumor lysis syndrome, prevention	3
Medical Necessity Criteria for Subsequent Clinical Review	4
Subsequent Medical Necessity Criteria	4
Gout or Tumor Lysis Syndrome, Prevention	4
Experimental or Investigational / Not Medically Necessary	4
References	4
Appendix A	5
Clinical Guideline Revision / History Information	6

Summary

Management for the prevention of recurrent gout flares and damage to joints and other tissues from urate crystal deposition includes drug therapy with the xanthine oxidase inhibitors allopurinol and

febuxostat (Uloric), lifestyle modifications, and other strategies for risk reduction. The use of urate-lowering drugs for the prevention of recurrent gout flares and disease progression is strongly recommended. Allopurinol is first line therapy for treatment and prevention of gout flares. Allopurinol should be started at 50 to 100mg per day and titrated to a maximally tolerated dose to achieve maximum urate lowering effect. Allopurinol dosing should be reduced if patients have renal impairment. Allopurinol also should not be started if a patient is positive for the HLA-B*5801 allele.

Febuxostat (Brand Name: Uloric) should be initiated after those who fail or have a contraindication to a maximally tolerated dose of allopurinol. Febuxostat is FDA approved for treating hyperuricemia to prevent gout flares and should not be used for the acute gout flare treatment. Febuxostat is taken as a 40 mg tablet once daily and may be increased to 80 mg once daily. While it is mainly used for gout, febuxostat also has evidence for use in preventing high uric acid levels after chemotherapy. It may be used to prevent a serious medical emergency called tumor lysis syndrome when Elitek (rasburicase) or allopurinol is not a good option.

Definitions

"Gout" is a condition where uric acid crystallizes and deposits in joints causing pain, redness, and swelling.

"Gout Flare" is a painful and disabling inflammatory arthritis caused by uric acid that usually involves a single joint but occasionally involves two or more joints.

"Gout Tophi" are caused by uric acid building up around joints. Tophi often look like swollen, bulbous growths around joints just under the skin.

"Hyperuricemia" is an elevated uric acid level in the blood.

"Tumor Lysis Syndrome" is a dangerous medical emergency that can happen after chemotherapy, when cancer cells break down and release its contents into the bloodstream.

"Xanthine oxidase inhibitors" are any substance that inhibits the activity of xanthine oxidase, an enzyme involved in purine metabolism. Inhibition of xanthine oxidase reduces the production of uric acid in the body

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Gout

The Plan considers febuxostat (Uloric) medically necessary when ALL the following criteria are met for the applicable indication listed below:

1. The member is at least 18 years of age; *AND*
2. The requested medication is being used for long-term management of hyperuricemia (i.e., not for treatment of acute attacks); *AND*
3. The member has documented evidence of ONE (1) of the following:
 - a. One (1) or more subcutaneous tophi; *or*
 - b. Evidence of radiographic damage (e.g., gouty bone erosion) attributable to gout; *or*
 - c. Frequent gout flares (defined as 2 or more per year); *or*
 - d. Has experienced more than 1 flare but have infrequent flares (fewer than 2 per year); *or*
 - e. Is experiencing first flare with comorbid moderate-to-severe chronic kidney disease (stage 3 or higher), serum urate concentration greater than 9 mg/dL, or urolithiasis; *AND*
4. The member has documentation of hyperuricemia demonstrated by a baseline (pre-treatment) serum uric acid level greater than or equal to (\geq) 6.8 mg/dL; *AND*
5. The member is unable to use or has adequately tried and failed at least a one-month (1) trial with allopurinol dosed at least 300 mg per day (dependent on renal function) (see [Appendix A](#), Table 1); *AND*
6. Chart documentation and supporting lab work are provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met, febuxostat (Uloric) will be approved for up to 12 months.

Tumor lysis syndrome, prevention

The Plan considers febuxostat (Uloric) medically necessary when ALL the following criteria are met for the applicable indication listed below:

1. The member is at least 18 years of age; *AND*
2. The member is at intermediate or high risk for tumor lysis syndrome (e.g., the member has leukemia, lymphoma, or solid tumor malignancies and is undergoing chemotherapy expected to result in tumor lysis and subsequent elevations of serum and urinary uric acid concentrations); *AND*
3. The member is unable to use or has tried and failed allopurinol; *AND*
4. Chart documentation is provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met, febuxostat (Uloric) will be approved for up to 12 months.

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Medical Necessity Criteria

Gout or Tumor Lysis Syndrome, Prevention

The plan considers febuxostat (Uloric) medically necessary when ONE (1) of the following since the member started therapy with febuxostat (Uloric):

1. Clinical remission or therapeutic benefit (e.g., cessation of gout flares, resolution of tophi, or improvement in patient physical function and health-related quality of life); *OR*
2. A reduction or normalization of laboratory evidence of hyperuricemia or TLS (e.g., serum uric acid, serum lactate dehydrogenase); *OR*
3. An avoidance of or reduction in metabolic complications and morbidity associated with tumor lysis syndrome, or the need for additional renal support (dialysis or hemofiltration).

If the above reauthorization criteria are met, the requested product will be authorized for up to 12 months.

Experimental or Investigational / Not Medically Necessary

febuxostat (Uloric) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

References

1. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. *Arthritis Res Ther*. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.
2. Bellos I, Kontzoglou K, Psyri A, Pergialiotis V. Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. *J Clin Pharm Ther*. 2019;44(4):525-533. doi:10.1111/jcpt.12839
3. Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. *Arthritis Care Res (Hoboken)*. 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.
4. Fernando Perez-Ruiz, MD, PhD. Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. UpToDate.com. May 22, 2020. Accessed August 20, 2020.
5. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760. doi:10.1002/acr.24180
6. FitzGerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. *Arthritis Care Res (Hoboken)*. 2018;70(5):659-671. doi:10.1002/acr.23500.
7. Kishimoto K, Kobayashi R, Hori D, Sano H, Suzuki D, Kobayashi K. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. *Anticancer Res*. 2017 Oct;37(10):5845-5849. doi: 10.21873/anticancer.12028.

8. Mandl P, D'Agostino MA, Navarro-Compán V, et al. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. *Ann Rheum Dis*. 2024 May 15;83(6):752-759. doi: 10.1136/ard-2023-224771.
9. National Institute for Health and Care Excellence (NICE). Gout: diagnosis and management (NG219). Published 09 Jun 2022. Available at: <https://www.nice.org.uk/guidance/ng219>. Accessed 02 Oct 2025.
10. Qaseem A, Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med*. 2017;166(1):58-68. doi:10.7326/M16-0570
11. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.
12. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum*. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
13. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. *Ann Rheum Dis*. 2014;73(2):328-335.
14. Spina M, Nagy Z, Ribera JM, et al; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. *Ann Oncol*. 2015;26(10):2155-2161. doi:10.1093/annonc/mdv317
15. Tamura K, Kawai Y, Kiguchi T, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. *Int J Clin Oncol*. 2016;21(5):996-1003. doi:10.1007/s10147-016-0971-3
16. Uloric (febuxostat) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; April 2023.
17. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. *N Engl J Med*. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
18. Zyloprim (allopurinol) [prescribing information]. East Brunswick, NJ: Casper Pharma; December 2018.

Appendix A

Table 1: Contraindications and Precautions for Use of Allopurinol

Safety Concerns	Description
Contraindications	<ul style="list-style-type: none"> Hypersensitivity to allopurinol or any of its components
Precautions	<ul style="list-style-type: none"> Gout flares: may occur during initiation of treatment, concurrent prophylactic treatment with colchicine or antiinflammatory agents is recommended. HLA-B*58:01 allele: is a genetic risk marker for severe skin reactions indicative of hypersensitivity to allopurinol. Individuals who are HLA-B*58:01-positive are at higher risk for allopurinol hypersensitivity syndrome. Some populations have a higher prevalence of HLA-B*58:01 allele. The use of allopurinol in individuals who are positive for the HLA-B*58:01 allele is not

	<p>recommended unless the benefits clearly outweigh the risks.</p> <ul style="list-style-type: none"> • Hepatotoxicity: Cases of reversible hepatotoxicity have occurred. If signs and symptoms of hepatotoxicity develop, evaluate liver function. • Myelosuppression: Bone marrow suppression has been reported with allopurinol. • Nephrotoxicity: allopurinol may affect kidney function. Lower doses should be used in those with decreased kidney function. • Skin Rash and Hypersensitivity: Allopurinol has been associated with serious and sometimes fatal dermatological reactions (e.g., Toxic Epidermal Necrolysis (TEN), Stevens-Johnson syndrome [SJS], Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]). Discontinue allopurinol at the first appearance of skin rash or other signs of hypersensitivity reaction.
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical Guideline Revision / History Information

Original Date: 11/05/2020

Reviewed/Revised: 10/14/2021, 12/01/2021, 9/15/2022, 9/21/2023, 12/19/2024, 01/01/2026